Cargando…
Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
Reactome describes biological pathways as chemical reactions that closely mirror the actual physical interactions that occur in the cell. Recent extensions of our data model accommodate the annotation of cancer and other disease processes. First, we have extended our class of protein modifications t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712731/ https://www.ncbi.nlm.nih.gov/pubmed/24213504 http://dx.doi.org/10.3390/cancers4041180 |
_version_ | 1782277109145665536 |
---|---|
author | Milacic, Marija Haw, Robin Rothfels, Karen Wu, Guanming Croft, David Hermjakob, Henning D’Eustachio, Peter Stein, Lincoln |
author_facet | Milacic, Marija Haw, Robin Rothfels, Karen Wu, Guanming Croft, David Hermjakob, Henning D’Eustachio, Peter Stein, Lincoln |
author_sort | Milacic, Marija |
collection | PubMed |
description | Reactome describes biological pathways as chemical reactions that closely mirror the actual physical interactions that occur in the cell. Recent extensions of our data model accommodate the annotation of cancer and other disease processes. First, we have extended our class of protein modifications to accommodate annotation of changes in amino acid sequence and the formation of fusion proteins to describe the proteins involved in disease processes. Second, we have added a disease attribute to reaction, pathway, and physical entity classes that uses disease ontology terms. To support the graphical representation of “cancer” pathways, we have adapted our Pathway Browser to display disease variants and events in a way that allows comparison with the wild type pathway, and shows connections between perturbations in cancer and other biological pathways. The curation of pathways associated with cancer, coupled with our efforts to create other disease-specific pathways, will interoperate with our existing pathway and network analysis tools. Using the Epidermal Growth Factor Receptor (EGFR) signaling pathway as an example, we show how Reactome annotates and presents the altered biological behavior of EGFR variants due to their altered kinase and ligand-binding properties, and the mode of action and specificity of anti-cancer therapeutics. |
format | Online Article Text |
id | pubmed-3712731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-37127312013-08-05 Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome Milacic, Marija Haw, Robin Rothfels, Karen Wu, Guanming Croft, David Hermjakob, Henning D’Eustachio, Peter Stein, Lincoln Cancers (Basel) Article Reactome describes biological pathways as chemical reactions that closely mirror the actual physical interactions that occur in the cell. Recent extensions of our data model accommodate the annotation of cancer and other disease processes. First, we have extended our class of protein modifications to accommodate annotation of changes in amino acid sequence and the formation of fusion proteins to describe the proteins involved in disease processes. Second, we have added a disease attribute to reaction, pathway, and physical entity classes that uses disease ontology terms. To support the graphical representation of “cancer” pathways, we have adapted our Pathway Browser to display disease variants and events in a way that allows comparison with the wild type pathway, and shows connections between perturbations in cancer and other biological pathways. The curation of pathways associated with cancer, coupled with our efforts to create other disease-specific pathways, will interoperate with our existing pathway and network analysis tools. Using the Epidermal Growth Factor Receptor (EGFR) signaling pathway as an example, we show how Reactome annotates and presents the altered biological behavior of EGFR variants due to their altered kinase and ligand-binding properties, and the mode of action and specificity of anti-cancer therapeutics. MDPI 2012-11-08 /pmc/articles/PMC3712731/ /pubmed/24213504 http://dx.doi.org/10.3390/cancers4041180 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Milacic, Marija Haw, Robin Rothfels, Karen Wu, Guanming Croft, David Hermjakob, Henning D’Eustachio, Peter Stein, Lincoln Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome |
title | Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome |
title_full | Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome |
title_fullStr | Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome |
title_full_unstemmed | Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome |
title_short | Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome |
title_sort | annotating cancer variants and anti-cancer therapeutics in reactome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712731/ https://www.ncbi.nlm.nih.gov/pubmed/24213504 http://dx.doi.org/10.3390/cancers4041180 |
work_keys_str_mv | AT milacicmarija annotatingcancervariantsandanticancertherapeuticsinreactome AT hawrobin annotatingcancervariantsandanticancertherapeuticsinreactome AT rothfelskaren annotatingcancervariantsandanticancertherapeuticsinreactome AT wuguanming annotatingcancervariantsandanticancertherapeuticsinreactome AT croftdavid annotatingcancervariantsandanticancertherapeuticsinreactome AT hermjakobhenning annotatingcancervariantsandanticancertherapeuticsinreactome AT deustachiopeter annotatingcancervariantsandanticancertherapeuticsinreactome AT steinlincoln annotatingcancervariantsandanticancertherapeuticsinreactome |